LAMP2 as a Biomarker Related to Prognosis and Immune Infiltration in Esophageal Cancer and Other Cancers: A Comprehensive Pan-Cancer Analysis

Frontiers in Oncology

Dan-man Liu¹  Shao-bo Zhang²  Xiao-min Li²  Ze-feng Xie²  Shu-huan Xie²  Yu Li²  Shan-peng Liu² 

[1] Breast Surgery Clinics, Guangdong Province Women and Children Hospital, Guangzhou, China;Thoracic Surgery Department, The First Affiliated Hospital of Shantou University Medical College, Shantou, China;

关键词: LAMP2;    esophageal cancer;    pan-cancer;    diagnostic;    prognosis;    immune infiltration;   

DOI  :  10.3389/fonc.2022.884448

来源: DOAJ

【 摘 要 】

Esophageal cancer (ESCA) is a common malignant tumor with poor prognosis. Accumulating evidence indicates an important role of lysosomal-associated membrane protein 2 (LAMP2) in the progression and development of various cancers. In this study, we obtained RNA-sequencing raw count data and the corresponding clinical information for ESCA samples from The Cancer Genome Atlas and Gene Expression Omnibus databases. We comprehensively investigated the expression and prognostic significance of LAMP2 and relationships between LAMP2 expression and prognosis, different clinicopathological parameters, and immune cell infiltration in ESCA. We also obtained the differentially expressed genes between the high LAMP2 expression and low LAMP2 expression groups in ESCA and performed a functional enrichment analysis of the 250 linked genes most positively related to LAMP2 expression. Moreover, we performed the pan-cancer analysis of LAMP2 to further analyze the role of LAMP2 in 25 commonly occurring types of human cancer. We also verified and compared the expression of LAMP2 in 40 samples of human ESCA tissue and adjacent tissues. The results indicated that LAMP2 expression was significantly upregulated in ESCA and various human cancers. In addition, LAMP2 expression was associated with certain clinicopathological parameters, prognosis, and immune infiltration in ESCA and the other types of cancer. Our study represents a comprehensive pan-cancer analysis of LAMP2 and supports the potential use of the modulation of LAMP2 in the management of ESCA and various cancers.

【 授权许可】

Unknown